Home › Funds › Samsara BioCapital, LLC › ARTV
Samsara BioCapital, LLC position in ARTV
ARTIVA BIOTHERAPEUTICS INC · Health Care
Samsara BioCapital, LLC reported holding 954,861 shares of ARTV (ARTIVA BIOTHERAPEUTICS INC) in its Q2 2026 13F filing — a position valued at US$9.3M, representing 0.76% of its reported portfolio and ranking #16 among its reported holdings. Samsara BioCapital, LLC has disclosed ARTV holdings in 5 of the last 8 reported quarters, going back to Q3 2024.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How Samsara BioCapital, LLC's ARTV position evolved
Samsara BioCapital, LLC first disclosed a stake in ARTV in Q3 2024 at 291,666 shares (US$4.5M). The position peaked in Q2 2026 at 954,861 shares, worth US$9.3M. Across 5 filings, Samsara BioCapital, LLC held the position steady without any share-count change. The most recent filing (Q2 2026) shows 954,861 shares valued at US$9.3M.
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2024 | 291.67K | $4.51M | New |
| Q4 2024 | 291.67K | $2.94M | Hold |
| Q1 2025 | 291.67K | $875.00K | Hold |
| Q2 2025 | 291.67K | $440.42K | Hold |
| Q2 2026 | 954.86K | $9.26M | New |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About ARTV and 13F data
ARTV (ARTIVA BIOTHERAPEUTICS INC) is a Health Care company. 61 other funds we track also report a position in ARTV — the largest reported positions include RA CAPITAL MANAGEMENT, L.P. (US$174.2M), 5AM Venture Management, LLC (US$22.8M), Venrock Adviser, LLC (US$19.8M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding ARTV
- RA CAPITAL MANAGEMENT, L.P. 17.96M sh · $174.17M · Q2 2026
- 5AM Venture Management, LLC 2.35M sh · $22.83M · Q2 2026
- Venrock Adviser, LLC 2.04M sh · $19.82M · Q2 2026
- Caligan Partners LP 1.74M sh · $16.84M · Q2 2026
- Blue Owl Capital Holdings LP 874.54K sh · $8.48M · Q2 2026
- Propel Bio Management, LLC 696.44K sh · $6.76M · Q2 2026
- SILVERARC CAPITAL MANAGEMENT, LLC 525.00K sh · $5.09M · Q2 2026
- ACUTA CAPITAL PARTNERS, LLC 260.42K sh · $2.53M · Q2 2026
- Revelation Capital Management, LLC 299.31K sh · $2.13M · Q3 2026
- KVP Capital Advisors, LP 200.00K sh · $1.94M · Q2 2026
- Velan Capital Investment Management LP 25.00K sh · $242.50K · Q2 2026
- Spark Investment Management LLC 16.50K sh · $160.05K · Q2 2026
More on Samsara BioCapital, LLC
FAQ
How long has Samsara BioCapital, LLC held ARTV?
Samsara BioCapital, LLC has disclosed ARTV holdings in 5 of the last 8 reported quarters, going back to Q3 2024.
What is Samsara BioCapital, LLC's current position in ARTV?
As of Q2 2026, Samsara BioCapital, LLC holds 954.86K shares of ARTV (ARTIVA BIOTHERAPEUTICS INC), valued at $9.26M, representing 0.76% of its reported portfolio and ranking #16.
Has Samsara BioCapital, LLC been buying or selling ARTV?
In the latest 13F filing (Q2 2026), Samsara BioCapital, LLC newly opened its position in ARTV. The position peaked in Q2 2026 at 954.86K shares.
Which other funds hold ARTV?
Other major institutional holders of ARTV include RA CAPITAL MANAGEMENT, L.P., 5AM Venture Management, LLC, Venrock Adviser, LLC, among 61 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.